Value Proposition:
· Unique mechanism of action that targets antibiotic-resistant infections
· Ability to target multiple stress resistance mechanisms in bacteria
· Broad range of application
Technology Description
· Researchers at Johns Hopkins have developed an antibacterial small molecule inhibitor that can be used to treat antibiotic resistant bacteria like Pseudomonas aeruginosa and Staphylococcus aureus. The small molecule inhibitor inhibits the stringent response in bacteria to make them susceptible to host derived stresses and antibiotics.
Unmet Need
Antibiotic resistant bacteria are a massive threat facing our healthcare system as they lead to increased prevalence of untreatable diseases and drastically increased healthcare costs. There are a select number of last result antibiotic combinations available for use like Colistin and Polymyxin B but even these often need to be used in combination with other therapies, and resistance to these combinations have more recently been described. Therefore, there is a strong need for new antibiotics to be developed with novel mechanisms of action to increase our ability to fight antimicrobial resistant bacteria and prevent disease.
Stage of Development
· Preclinical efficacy data available
Publication
· N/A
